Dapirolizumab pegol

DB16131Investigational

Dapirolizumab pegol is under investigation in clinical trial NCT02804763 (A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus).

Mechanism: Pharmacologically active on CD40 ligand
Curator reviewed
Also known as: Immunoglobulin fab' g1-kappa pegylated, anti-(homo sapiens cd40lg (cd40 ligand, cd40l, tumor necrosis factor ligand superfamily member 5, tnfsf5, tumor necrosis factor related activation protein, trap, cd154)), pegylated humanized monoclonal antibody
Code names: CDP-7657

Resolves to

Compound

UNIIN4606MB5HMCAS1416147-64-2

Targets

P29965CD40LG

What you can answer from here — as of March 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Dapirolizumab pegol, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account